nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
ADMA and hyperhomocysteinemia
|
Dayal, Sanjana |
|
2005 |
vmr-2 |
1_suppl |
p. S27-S33 |
artikel |
2 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study
|
Böger, Rainer H |
|
2005 |
vmr-2 |
1_suppl |
p. S97-S102 |
artikel |
3 |
ADMA: an emerging cardiovascular risk factor
|
Böger, Rainer H |
|
2005 |
vmr-2 |
1_suppl |
p. S1-S2 |
artikel |
4 |
ADMA: its role in vascular disease
|
Cooke, John P |
|
2005 |
vmr-2 |
1_suppl |
p. S11-S17 |
artikel |
5 |
ADMA metabolism and clearance
|
Teerlink, Tom |
|
2005 |
vmr-2 |
1_suppl |
p. S73-S81 |
artikel |
6 |
Angiogenesis/vasculogenesis
|
|
|
2006 |
vmr-2 |
1_suppl |
p. S1-S17 |
artikel |
7 |
Arginine metabolism in vascular biology and disease
|
Morris, Sidney M |
|
2005 |
vmr-2 |
1_suppl |
p. S83-S87 |
artikel |
8 |
Asymmetric dimethylarginine (ADMA) accelerates cell senescence
|
Bode-Böger, Stefanie M |
|
2005 |
vmr-2 |
1_suppl |
p. S65-S71 |
artikel |
9 |
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
|
Böger, Rainer H |
|
2005 |
vmr-2 |
1_suppl |
p. S19-S25 |
artikel |
10 |
Atherothrombosis - the neurologist’s point of view
|
Leys, Didier |
|
2001 |
vmr-2 |
1_suppl |
p. 17-19 |
artikel |
11 |
DDAH gene and cardiovascular risk
|
Valkonen, Veli-Pekka |
|
2005 |
vmr-2 |
1_suppl |
p. S45-S48 |
artikel |
12 |
Endogenous production of nitric oxide synthase inhibitors
|
Anthony, Shelagh |
|
2005 |
vmr-2 |
1_suppl |
p. S3-S9 |
artikel |
13 |
Foreword
|
Belch, Jill |
|
2001 |
vmr-2 |
1_suppl |
p. 1 |
artikel |
14 |
Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA
|
Sydow, Karsten |
|
2005 |
vmr-2 |
1_suppl |
p. S35-S43 |
artikel |
15 |
PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program
|
Hirsch, Alan T |
|
2001 |
vmr-2 |
1_suppl |
p. 9-12 |
artikel |
16 |
Peripheral arterial disease - epidemiological aspects
|
Criqui, Michael H |
|
2001 |
vmr-2 |
1_suppl |
p. 3-7 |
artikel |
17 |
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)
|
Maas, Renke |
|
2005 |
vmr-2 |
1_suppl |
p. S49-S57 |
artikel |
18 |
Quantification of ADMA: analytical approaches
|
Schwedhelm, Edzard |
|
2005 |
vmr-2 |
1_suppl |
p. S89-S95 |
artikel |
19 |
Rationale for the use of platelet aggregation inhibitors in PAD patients
|
Agnelli, Giancarlo |
|
2001 |
vmr-2 |
1_suppl |
p. 13-15 |
artikel |
20 |
Spotlight on endothelial progenitor cell inhibitors: short review
|
Thum, Thomas |
|
2005 |
vmr-2 |
1_suppl |
p. S59-S64 |
artikel |